Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.
Haemalogix has raised $7.4M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2021.
Haemalogix's investors include Cicada Innovations, Platinum Asset Management.
Haemalogix is headquartered in Sydney, Australia.
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.
Haemalogix is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Haemalogix — Funding & Investors." VCBacked, September 8, 2021, https://www.vcbacked.co/company/haemalogix. Accessed September 30, 2026.
VCBacked. (2021). Haemalogix — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/haemalogix
{{cite web |title=Haemalogix — Funding & Investors |url=https://www.vcbacked.co/company/haemalogix |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated